生物制剂在过去几十年中在癌症、免疫学和糖尿病等疾病领域取得了显著的成功。然而，创新生物制剂药物的高昂成本导致了全球可及性不均。尽管全球85%的人口生活在低收入和中等收入国家（LMIC）中，但单克隆抗体的销售额的80%归因于西方国家，突显了明显的市场失衡。本文通过比较生物类似药和仿制药之间的类比和差异，旨在通过审视低收入和中等收入国家的生物制剂低可及性的可能原因（包括经济和社会原因），展示了LMIC与HIC之间的差距，并为解决LMIC中尚未满足的医疗需求提出了对策。要实现生物治疗药物在所有地区和国家的可及性，需要各方利用生物类似药提供的机遇，通过承诺透明合作来实现。

Biologics have shown marked success over the past decades in disease areas as cancer, immunology and diabetes. However, elevated costs of innovative biologic medicines have led to an inequity in accessibility across the world. While 85% of the world's population lives in low- and middle- income countries (LMIC), 80% of the sales of monoclonal antibodies are attributed to Western countries, highlighting the pronounced market imbalance.This perspective paper draws some analogies as well as differences between biosimilars and generics, aims to address the unmet need for treatment with biologics in LMICs by reviewing possible causes, economic and social, of low access, displaying the disparity between LMICs and HIC, and suggets countermeasures for this unmet medical need in LMICs.It is up to all stakeholders to capitalize on the opportunity that biosimilars provide, mostly by commiting to transparent collaboration, to make biotherapeutics accessible to all, regardless of region or country of residence.